UBC PiMS Research Group

Pharmacoepidemiology in Multiple Sclerosis Research Group

New article published in The Lancet Neurology

PiMS member José M A Wijnands article, "Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study" was recently published in Lancet Neurology.

What’s new for ‘microbiota multiple sclerosis’ in PubMed

Helen Tremlett's new article, "The gut microbiome in human neurological disease: A review", was recently published in Annals of Neurology.

Association between anti-depressants drugs on the progression of multiple sclerosis.

Researchers found no evidence to suggest that exposure to the antidepressants ‘selective serotonin reuptake inhibitors’ were associated with a delay in MS disability accumulation or progression.

Unique Relationship Found Between Gut Microbiota and Immune Markers in Kids with MS

Children with multiple sclerosis (MS) may show a disruption in the balance of bacteria in the gut as early as two years into the disease course, suggests new findings from Dr. Helen Tremlett.
❙ ❙ « 1 / 4 »

Welcome to the new UBC PiMS Group Website

Our Research Group is physically located within the University of British Columbia’s hospital. We are also part of the Brain Research Centre, Faculty and Department of Medicine and Division of Neurology. If that wasn’t enough, we are also affiliated with the Vancouver Coastal Health Research Institute.

a place of mind, The University of British Columbia

Pharmacoepidemiology in MS (PiMS)
2211 Wesbrook Mall,
Vancouver, BC, V6T 2B5, Canada
Email:

Emergency Procedures | Accessibility | Contact UBC  | © Copyright The University of British Columbia